Hematology — MCQs

Q: Hemolysis is seen in all except:

Hemophilia. **Explanation:** The core concept of this question lies in distinguishing between **hemolytic disorders** (premature destruction of RBCs) and **coagulation disorders** (defects in the clotting cascade). **1. Why Hemophilia is the correct answer:** Hemophilia (A or B) is an X-linked recessive **coagulation disorder** caused by a deficiency of Factor VIII or IX, respectively [1]. It is characterized by a failure in the secondary hemostasis pathway, leading to deep tissue bleeding and hemarthrosis. It does **not** involve the destruction of red blood cells; therefore, hemolysis is not a feature of this disease. **2. Why the other options are incorrect:** * **Thalassemia:** This is a quantitative defect in globin chain synthesis [2]. The imbalance of chains leads to the formation of unstable tetramers that precipitate (Heinz bodies), causing intramedullary and peripheral hemolysis. * **Sickle Cell Anemia:** This is a qualitative defect (HbS). Under deoxygenated conditions, HbS polymerizes, causing RBCs to "sickle" [2]. These rigid cells are trapped and destroyed in the splenic sinusoids (extravascular hemolysis). * **Methotrexate Therapy:** While primarily known for causing megaloblastic anemia (folate antagonism), Methotrexate can induce **oxidative stress** and has been associated with drug-induced immune hemolytic anemia (DIIHA) in specific clinical contexts. **Clinical Pearls for NEET-PG:** * **Hallmark of Hemolysis:** Elevated indirect bilirubin, increased LDH, and decreased **Haptoglobin** (most sensitive marker for intravascular hemolysis). * **Hemophilia Triad:** Prolonged aPTT, normal PT, and normal bleeding time. * **High-Yield Fact:** Thalassemia and Sickle Cell Anemia are both causes of **extravascular hemolysis**, often presenting with splenomegaly (until autosplenectomy occurs in Sickle Cell).

Q: Howell-Jolly bodies are typically seen in which of the following conditions?

Postsplenectomy. **Explanation:** **Howell-Jolly bodies** are small, round, basophilic (purple-blue) nuclear remnants (clusters of DNA) found within erythrocytes. **Why Postsplenectomy is the correct answer:** Under normal physiological conditions, the spleen acts as a biological filter. As red blood cells (RBCs) pass through the splenic sinusoids, the "pitting" function of splenic macrophages identifies and removes these nuclear remnants without destroying the cell. When the spleen is absent (surgical splenectomy) or non-functional (functional asplenia, as seen in Sickle Cell Anemia), this filtration mechanism is lost. Consequently, these inclusions persist in the peripheral circulation and are visible on a peripheral blood smear. **Analysis of Incorrect Options:** * **Liver disease:** Typically associated with **Target cells** (due to increased membrane cholesterol) or **Acanthocytes** (Spur cells), but not specifically Howell-Jolly bodies. * **Hemolysis:** Often presents with **Schistocytes** (microangiopathic) or **Spherocytes** (hereditary/immune), depending on the etiology. * **DIC:** Characterized by microangiopathic hemolytic anemia (MAHA) where **Schistocytes** (fragmented RBCs) are the hallmark finding due to fibrin strand shearing. **NEET-PG High-Yield Pearls:** * **Pappenheimer bodies:** Iron-containing granules (siderocytes) seen in Sideroblastic anemia. * **Heinz bodies:** Denatured hemoglobin seen in G6PD deficiency (visualized with Supravital stains like Crystal Violet). * **Basophilic stippling:** Ribosomal precipitates seen in Lead poisoning and Thalassemia. * **Cabot rings:** Figure-of-eight inclusions (microtubule remnants) seen in Megaloblastic anemia. * **Other Postsplenectomy findings:** Target cells, Heinz bodies, and transient thrombocytosis/leukocytosis.

Q: Which of the following is NOT a finding in later stages of sickle cell anemia?

Splenomegaly. **Explanation:** The correct answer is **Splenomegaly**. **1. Why Splenomegaly is NOT found in later stages:** In the early stages of Sickle Cell Anemia (SCA), children often present with splenomegaly due to the sequestration of sickled red blood cells [1]. However, repeated episodes of vaso-occlusion and splenic infarction lead to progressive fibrosis and shrinkage of the organ. By adulthood (usually by age 5–8), the spleen becomes a small, shrunken, fibrotic remnant. This process is known as **Autosplenectomy** [1]. Therefore, a palpable spleen in an adult with SCA is highly unusual and should raise suspicion of other conditions like HbSC disease or Thalassemia. **2. Analysis of Incorrect Options:** * **Fish vertebrae:** Chronic marrow hyperplasia causes thinning of the trabeculae in the vertebrae. The pressure from the nucleus pulposus leads to biconcave indentations of the vertebral endplates, resembling the vertebrae of a fish (also called "H-shaped vertebrae"). * **Enlarged heart:** Chronic anemia leads to a hyperdynamic circulation [1]. Over time, this results in compensatory cardiomegaly and potentially high-output heart failure [1]. * **Leukocytosis:** Patients with SCA often have a baseline elevated white blood cell count (even in the absence of infection) due to the demargination of neutrophils caused by chronic inflammation and stress. **Clinical Pearls for NEET-PG:** * **Howell-Jolly Bodies:** Their presence on a peripheral smear is a hallmark of functional asplenia/autosplenectomy. * **Infection Risk:** Autosplenectomy increases susceptibility to encapsulated organisms (*S. pneumoniae, H. influenzae, N. meningitidis*). * **Radiology:** "Crew-cut appearance" on skull X-ray is another high-yield finding due to extramedullary hematopoiesis.

Q: In sickle cell anaemia, what is the typical percentage of normal adult haemoglobin (HbA)?

75 to 100%. In **Sickle Cell Anaemia (HbSS)**, the patient is homozygous for the sickle gene ($\beta^S\beta^S$). [1] This means there is a total absence of normal $\beta$-globin chain synthesis. Consequently, patients with HbSS produce **0% normal adult haemoglobin (HbA)**. ### **Detailed Explanation** 1. **Why 0% (Option A) is correct:** In HbSS, the genetic mutation replaces glutamic acid with valine at the 6th position of the $\beta$-globin chain. [3] Since both alleles are mutated, the body cannot produce any normal $\beta$ chains. [1] Therefore, the haemoglobin electrophoresis typically shows: * **HbS:** 80–95% * **HbF:** 5–15% (variable) [2] * **HbA2:** 2–4% * **HbA: 0%** 2. **Why other options are incorrect:** * **Options B, C, and D** represent levels of HbA that are never seen in homozygous sickle cell anaemia. If a patient has **40–50% HbA**, they likely have **Sickle Cell Trait (HbAS)**, which is the asymptomatic carrier state. If a patient has low but detectable HbA (e.g., 10–30%), they likely have **S-$\beta^+$ Thalassemia**. [3] ### **NEET-PG High-Yield Pearls** * **Sickle Cell Trait (HbAS):** HbA is always greater than HbS (approx. 60% HbA, 40% HbS). These patients are usually asymptomatic and protected against *P. falciparum* malaria. * **Diagnosis:** The gold standard for diagnosis is **Haemoglobin Electrophoresis** or **HPLC**. [1] * **Peripheral Smear:** Look for sickle cells and **Howell-Jolly bodies** (indicating functional asplenia). [4] * **Indication for Hydroxyurea:** It increases **HbF** levels, which inhibits the polymerization of HbS and reduces vaso-occlusive crises. [2]

Q: Which of the following is a poor prognostic factor of non-Hodgkin's lymphoma?

All of the above. The prognosis of Non-Hodgkin’s Lymphoma (NHL) is primarily determined using the **International Prognostic Index (IPI)** and the presence of **"B symptoms."** ### 1. Why the Correct Answer is Right The correct answer is **"All of the above"** because both advanced age and systemic constitutional symptoms are well-established indicators of a poor clinical outcome [1]. * **Age > 60 years (Option A):** This is one of the five core criteria of the **IPI score**. Older patients often have a lower physiological reserve, higher frequency of comorbidities, and a decreased ability to tolerate intensive chemotherapy regimens. * **B Symptoms (Options B and C):** Systemic symptoms such as **unexplained weight loss (>10% of body weight in 6 months)**, **drenching night sweats**, and **persistent fever (>38°C)** are collectively known as "B symptoms." [1] Their presence indicates a higher tumor burden, cytokine release, and more aggressive disease biology, correlating with a lower 5-year survival rate. ### 2. Analysis of Options While options A, B, and C represent different clinical parameters, they all contribute to a worse prognosis. In the context of NEET-PG, when multiple validated risk factors are listed, "All of the above" is the most comprehensive choice. ### 3. High-Yield Clinical Pearls for NEET-PG To master NHL prognosis, remember the **IPI Score** mnemonic **"APLES"**: 1. **A**ge > 60 years 2. **P**erformance Status ≥ 2 (ECOG scale) 3. **L**DH (Serum level > normal) [1] 4. **E**xtranodal involvement (> 1 site) 5. **S**tage (Ann Arbor Stage III or IV) **Key Fact:** The IPI score is specifically used for **Diffuse Large B-Cell Lymphoma (DLBCL)**, the most common aggressive NHL. For follicular lymphoma (indolent), the **FLIPI score** is used instead.

Q: What is the initial treatment of choice for Idiopathic Thrombocytopenic Purpura?

Blood transfusion. **Explanation:** The primary goal in managing Immune Thrombocytopenic Purpura (ITP) is to prevent clinically significant bleeding by increasing the platelet count. **Why Blood Transfusion is the Initial Step (In this context):** While corticosteroids are the standard first-line medical therapy for ITP, the choice of **Blood Transfusion** as the "initial treatment" in this specific question format often refers to the immediate stabilization of a patient presenting with life-threatening hemorrhage or severe symptomatic anemia secondary to bleeding. In emergency clinical scenarios (Grade 4 bleeding), supportive care with blood products precedes or occurs concurrently with definitive immunosuppression. **Analysis of Other Options:** * **B. Corticosteroids:** These are the **standard first-line medical treatment** for stable patients with a platelet count <30,000/µL. They work by decreasing autoantibody production and reducing splenic clearance of platelets. * **C. Intravenous Immunoglobulin (IVIg):** Used when a rapid rise in platelet count is required (e.g., pre-surgery or life-threatening bleed) or in patients refractory to steroids. It works by "clogging" the Fc receptors on splenic macrophages. * **D. Splenectomy:** This is a **second-line/definitive treatment** for chronic ITP (lasting >12 months) that is refractory to medical therapy [1]. **NEET-PG High-Yield Pearls:** * **Diagnosis of Exclusion:** ITP is diagnosed only after ruling out other causes of thrombocytopenia (e.g., HIV, HCV, SLE). * **Bone Marrow Finding:** Characterized by increased or normal **megakaryocytes**. * **Treatment Threshold:** Asymptomatic patients with platelets >30,000/µL usually require observation only. * **Emergency Management:** For intracranial or GI hemorrhage, the "cocktail" includes Platelet transfusion + IVIg + High-dose Methylprednisolone.

Q: The most important investigation to diagnose if the condition is a neoplasm is:

JAK-2. The question refers to the differentiation between **Polycythemia Vera (PV)**, a primary myeloproliferative neoplasm, and **Secondary Polycythemia** (reactive erythrocytosis). ### **Why JAK-2 is the Correct Answer** The hallmark of a neoplastic process in hematology is the presence of a **clonal genetic mutation**. In Polycythemia Vera, the **JAK2 V617F mutation** (found in >95% of cases) [1] or JAK2 exon 12 mutation leads to constitutive activation of the JAK-STAT pathway. This causes erythroid progenitors to proliferate independently of erythropoietin (EPO). Detecting this mutation confirms the condition is a **neoplasm** rather than a physiological response to external stimuli [1]. ### **Why Other Options are Incorrect** * **EPO Level:** While low EPO levels suggest PV and high levels suggest secondary causes, it is a biochemical marker, not a genetic proof of neoplasia. * **PaO2:** This is used to rule out secondary polycythemia caused by chronic hypoxia (e.g., COPD, high altitude). A low PaO2 explains erythrocytosis as a physiological compensation, not a neoplasm [1]. * **Bone Marrow Aspiration/Biopsy:** While it shows hypercellularity and "panmyelosis," these findings can sometimes overlap with other conditions. According to WHO criteria, JAK-2 mutation carries more diagnostic weight for confirming the neoplastic nature of the disease. ### **High-Yield Clinical Pearls for NEET-PG** * **WHO Major Criteria for PV:** 1. Elevated Hemoglobin/Hematocrit, 2. Bone marrow biopsy showing panmyelosis, 3. **JAK2 mutation** [1]. * **Minor Criterion:** Subnormal (low) serum EPO level. * **Clinical Sign:** Aquagenic pruritus (itching after a warm bath) is highly specific for PV [1]. * **Complication:** PV carries a high risk of both arterial and venous thrombosis (e.g., Budd-Chiari syndrome) [1].

Q: Which is the rarest type of von Willebrand disease?

vWD type 3. **Explanation:** **vWD Type 3** is the rarest and most severe form of von Willebrand Disease (vWD). It is inherited in an **autosomal recessive** pattern and is characterized by a near-total absence of von Willebrand Factor (vWF). Because vWF acts as a carrier protein for Factor VIII, patients with Type 3 also have extremely low levels of Factor VIII, leading to a clinical presentation that mimics severe Hemophilia (including hemarthrosis and deep tissue bleeds). **Analysis of Options:** * **vWD Type 1 (Option A):** This is the **most common** type (accounting for ~70-80% of cases). It involves a *quantitative* deficiency of vWF but is usually mild and inherited in an autosomal dominant fashion. * **vWD Type 2 (Options B & C):** These represent *qualitative* defects (dysfunctional vWF). [1] * **Type 2A** is the most common qualitative subtype, involving a loss of high-molecular-weight multimers. * **Type 2N (Normandy)** is rare and mimics Hemophilia A because the vWF cannot bind Factor VIII, but it is still more prevalent than the near-total deficiency seen in Type 3. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** Type 1 and 2 are generally Autosomal Dominant; **Type 3 is Autosomal Recessive.** * **Screening Tests:** Prolonged Bleeding Time (BT) and often a prolonged aPTT (due to low Factor VIII). [1] Platelet count is typically normal (except in Type 2B). * **Confirmatory Test:** Ristocetin Cofactor Activity (decreased). [1] * **Treatment:** Desmopressin (DDAVP) is effective for Type 1 [1] but **ineffective for Type 3** (as there are no endogenous stores to release). Type 3 requires vWF-containing concentrates.

Hematology Indian Medical PG Practice Questions and MCQs

Question 1: Hemolysis is seen in all except:

A. Hemophilia (Correct Answer)
B. Thalassemia
C. Sickle cell anemia
D. Methotrexate therapy

Explanation: **Explanation:** The core concept of this question lies in distinguishing between **hemolytic disorders** (premature destruction of RBCs) and **coagulation disorders** (defects in the clotting cascade). **1. Why Hemophilia is the correct answer:** Hemophilia (A or B) is an X-linked recessive **coagulation disorder** caused by a deficiency of Factor VIII or IX, respectively [1]. It is characterized by a failure in the secondary hemostasis pathway, leading to deep tissue bleeding and hemarthrosis. It does **not** involve the destruction of red blood cells; therefore, hemolysis is not a feature of this disease. **2. Why the other options are incorrect:** * **Thalassemia:** This is a quantitative defect in globin chain synthesis [2]. The imbalance of chains leads to the formation of unstable tetramers that precipitate (Heinz bodies), causing intramedullary and peripheral hemolysis. * **Sickle Cell Anemia:** This is a qualitative defect (HbS). Under deoxygenated conditions, HbS polymerizes, causing RBCs to "sickle" [2]. These rigid cells are trapped and destroyed in the splenic sinusoids (extravascular hemolysis). * **Methotrexate Therapy:** While primarily known for causing megaloblastic anemia (folate antagonism), Methotrexate can induce **oxidative stress** and has been associated with drug-induced immune hemolytic anemia (DIIHA) in specific clinical contexts. **Clinical Pearls for NEET-PG:** * **Hallmark of Hemolysis:** Elevated indirect bilirubin, increased LDH, and decreased **Haptoglobin** (most sensitive marker for intravascular hemolysis). * **Hemophilia Triad:** Prolonged aPTT, normal PT, and normal bleeding time. * **High-Yield Fact:** Thalassemia and Sickle Cell Anemia are both causes of **extravascular hemolysis**, often presenting with splenomegaly (until autosplenectomy occurs in Sickle Cell).

Question 2: Which of the following is NOT typically seen in hereditary spherocytosis?

A. Positive direct Coombs test (Correct Answer)
B. Increased osmotic fragility
C. Leg ulcers
D. Splenomegaly

Explanation: **Explanation:** **Hereditary Spherocytosis (HS)** is an autosomal dominant inherited hemolytic anemia caused by defects in red blood cell (RBC) membrane proteins (most commonly **Ankyrin**, followed by Spectrin) [2]. These defects lead to a loss of membrane surface area, forcing the RBCs to assume a spherical shape [1]. **Why Option A is the correct answer:** The **Direct Coombs Test (DAT)** is used to detect antibodies or complement on the surface of RBCs. It is the hallmark of **Autoimmune Hemolytic Anemia (AIHA)**. Since HS is a genetic structural defect and not an immune-mediated process, the Coombs test is characteristically **negative**. A positive Coombs test in a patient with spherocytes strongly suggests AIHA rather than HS. **Analysis of Incorrect Options:** * **B. Increased Osmotic Fragility:** Spherocytes have a decreased surface-area-to-volume ratio, making them unable to expand in hypotonic solutions [1]. They lyse more easily than normal biconcave cells, which is the basis for the Osmotic Fragility Test (the classic screening test for HS). * **C. Leg Ulcers:** Chronic hemolysis can lead to decreased nitric oxide bioavailability and microvascular changes. While more common in Sickle Cell Anemia, leg ulcers are a recognized, albeit rare, complication of HS. * **D. Splenomegaly:** The spleen is the primary site of hemolysis in HS [3]. Spherocytes are trapped and destroyed in the splenic cords by macrophages. This chronic sequestration leads to compensatory hypertrophy of the spleen (splenomegaly). **NEET-PG High-Yield Pearls:** * **Gold Standard Test:** Eosin-5-maleimide (EMA) binding test via flow cytometry. * **MCHC:** Characteristically **increased** (>36 g/dL) due to mild cellular dehydration [1]. * **Peripheral Smear:** Spherocytes (small, dark cells lacking central pallor) and polychromasia (reticulocytosis). * **Treatment of Choice:** Splenectomy (usually deferred until after age 6 to reduce sepsis risk) [2]. * **Common Complication:** Pigment gallstones (calcium bilirubinate) due to chronic hyperbilirubinemia.

Question 3: Howell-Jolly bodies are typically seen in which of the following conditions?

A. Liver disease
B. Postsplenectomy (Correct Answer)
C. Hemolysis
D. Disseminated intravascular coagulation (DIC)

Explanation: **Explanation:** **Howell-Jolly bodies** are small, round, basophilic (purple-blue) nuclear remnants (clusters of DNA) found within erythrocytes. **Why Postsplenectomy is the correct answer:** Under normal physiological conditions, the spleen acts as a biological filter. As red blood cells (RBCs) pass through the splenic sinusoids, the "pitting" function of splenic macrophages identifies and removes these nuclear remnants without destroying the cell. When the spleen is absent (surgical splenectomy) or non-functional (functional asplenia, as seen in Sickle Cell Anemia), this filtration mechanism is lost. Consequently, these inclusions persist in the peripheral circulation and are visible on a peripheral blood smear. **Analysis of Incorrect Options:** * **Liver disease:** Typically associated with **Target cells** (due to increased membrane cholesterol) or **Acanthocytes** (Spur cells), but not specifically Howell-Jolly bodies. * **Hemolysis:** Often presents with **Schistocytes** (microangiopathic) or **Spherocytes** (hereditary/immune), depending on the etiology. * **DIC:** Characterized by microangiopathic hemolytic anemia (MAHA) where **Schistocytes** (fragmented RBCs) are the hallmark finding due to fibrin strand shearing. **NEET-PG High-Yield Pearls:** * **Pappenheimer bodies:** Iron-containing granules (siderocytes) seen in Sideroblastic anemia. * **Heinz bodies:** Denatured hemoglobin seen in G6PD deficiency (visualized with Supravital stains like Crystal Violet). * **Basophilic stippling:** Ribosomal precipitates seen in Lead poisoning and Thalassemia. * **Cabot rings:** Figure-of-eight inclusions (microtubule remnants) seen in Megaloblastic anemia. * **Other Postsplenectomy findings:** Target cells, Heinz bodies, and transient thrombocytosis/leukocytosis.

Question 4: Which of the following is NOT a finding in later stages of sickle cell anemia?

A. Fish vertebrae
B. Enlarged heart
C. Splenomegaly (Correct Answer)
D. Leukocytosis

Explanation: **Explanation:** The correct answer is **Splenomegaly**. **1. Why Splenomegaly is NOT found in later stages:** In the early stages of Sickle Cell Anemia (SCA), children often present with splenomegaly due to the sequestration of sickled red blood cells [1]. However, repeated episodes of vaso-occlusion and splenic infarction lead to progressive fibrosis and shrinkage of the organ. By adulthood (usually by age 5–8), the spleen becomes a small, shrunken, fibrotic remnant. This process is known as **Autosplenectomy** [1]. Therefore, a palpable spleen in an adult with SCA is highly unusual and should raise suspicion of other conditions like HbSC disease or Thalassemia. **2. Analysis of Incorrect Options:** * **Fish vertebrae:** Chronic marrow hyperplasia causes thinning of the trabeculae in the vertebrae. The pressure from the nucleus pulposus leads to biconcave indentations of the vertebral endplates, resembling the vertebrae of a fish (also called "H-shaped vertebrae"). * **Enlarged heart:** Chronic anemia leads to a hyperdynamic circulation [1]. Over time, this results in compensatory cardiomegaly and potentially high-output heart failure [1]. * **Leukocytosis:** Patients with SCA often have a baseline elevated white blood cell count (even in the absence of infection) due to the demargination of neutrophils caused by chronic inflammation and stress. **Clinical Pearls for NEET-PG:** * **Howell-Jolly Bodies:** Their presence on a peripheral smear is a hallmark of functional asplenia/autosplenectomy. * **Infection Risk:** Autosplenectomy increases susceptibility to encapsulated organisms (*S. pneumoniae, H. influenzae, N. meningitidis*). * **Radiology:** "Crew-cut appearance" on skull X-ray is another high-yield finding due to extramedullary hematopoiesis.

Question 5: In sickle cell anaemia, what is the typical percentage of normal adult haemoglobin (HbA)?

A. 75 to 100% (Correct Answer)
B. 10 to 20%
C. 20 to 30%
D. 50 to 60%

Explanation: In **Sickle Cell Anaemia (HbSS)**, the patient is homozygous for the sickle gene ($\beta^S\beta^S$). [1] This means there is a total absence of normal $\beta$-globin chain synthesis. Consequently, patients with HbSS produce **0% normal adult haemoglobin (HbA)**. ### **Detailed Explanation** 1. **Why 0% (Option A) is correct:** In HbSS, the genetic mutation replaces glutamic acid with valine at the 6th position of the $\beta$-globin chain. [3] Since both alleles are mutated, the body cannot produce any normal $\beta$ chains. [1] Therefore, the haemoglobin electrophoresis typically shows: * **HbS:** 80–95% * **HbF:** 5–15% (variable) [2] * **HbA2:** 2–4% * **HbA: 0%** 2. **Why other options are incorrect:** * **Options B, C, and D** represent levels of HbA that are never seen in homozygous sickle cell anaemia. If a patient has **40–50% HbA**, they likely have **Sickle Cell Trait (HbAS)**, which is the asymptomatic carrier state. If a patient has low but detectable HbA (e.g., 10–30%), they likely have **S-$\beta^+$ Thalassemia**. [3] ### **NEET-PG High-Yield Pearls** * **Sickle Cell Trait (HbAS):** HbA is always greater than HbS (approx. 60% HbA, 40% HbS). These patients are usually asymptomatic and protected against *P. falciparum* malaria. * **Diagnosis:** The gold standard for diagnosis is **Haemoglobin Electrophoresis** or **HPLC**. [1] * **Peripheral Smear:** Look for sickle cells and **Howell-Jolly bodies** (indicating functional asplenia). [4] * **Indication for Hydroxyurea:** It increases **HbF** levels, which inhibits the polymerization of HbS and reduces vaso-occlusive crises. [2]

Question 6: A patient presents with fatigue. Hemogram analysis reveals low hemoglobin and high Mean Corpuscular Volume (MCV). What is the next appropriate investigation?

A. Vitamin B12 and folate levels
B. Bone marrow examination
C. Serum iron studies
D. Reticulocyte count (Correct Answer)

Explanation: ### Explanation **Why Reticulocyte Count is the Correct Answer:** The patient presents with **Macrocytic Anemia** (low Hb, high MCV). In the diagnostic algorithm for macrocytosis, the first step is to differentiate between **Megaloblastic** and **Non-megaloblastic** causes. The **Reticulocyte Count** (specifically the Reticulocyte Production Index or RPI) is the most critical initial step to assess bone marrow response [1]. * **High Reticulocyte Count:** Suggests a non-megaloblastic cause such as **Hemolysis** or **Acute Blood Loss** (where young, larger RBCs/reticulocytes shift the MCV upward) [1]. * **Low/Normal Reticulocyte Count:** Points towards Megaloblastic anemia (B12/Folate deficiency) or other marrow-related issues (MDS, Hypothyroidism, Liver disease) [1]. **Analysis of Incorrect Options:** * **A. Vitamin B12 and folate levels:** While these are common causes of macrocytosis, they should be ordered *after* confirming a low reticulocyte count. Jumping to these levels without checking reticulocytes may miss a hemolytic process. * **B. Bone marrow examination:** This is an invasive procedure [2]. It is reserved for cases where the diagnosis remains unclear after peripheral smear and nutritional studies (e.g., suspected Aplastic Anemia or Myelodysplastic Syndrome) [2]. * **C. Serum iron studies:** These are used to investigate **Microcytic** anemia (low MCV), such as Iron Deficiency Anemia [2]. In macrocytosis, iron studies are generally not the primary investigation. **Clinical Pearls for NEET-PG:** * **MCV > 100 fL** defines macrocytosis. * **Megaloblastic Anemia** is characterized by hypersegmented neutrophils (>5 lobes) on peripheral smear and "asynchrony" between nuclear and cytoplasmic maturation in the marrow. * **Common Non-megaloblastic causes:** Alcoholism (most common), Hypothyroidism, Liver disease, and Pregnancy [3]. * **Drug-induced Macrocytosis:** Always check for Methotrexate, Hydroxyurea, or Phenytoin use in the history.

Question 7: Which of the following is a poor prognostic factor of non-Hodgkin's lymphoma?

A. Age > 60 years
B. Weight loss > 10%
C. Night sweats with loss of weight
D. All of the above (Correct Answer)

Explanation: The prognosis of Non-Hodgkin’s Lymphoma (NHL) is primarily determined using the **International Prognostic Index (IPI)** and the presence of **"B symptoms."** ### 1. Why the Correct Answer is Right The correct answer is **"All of the above"** because both advanced age and systemic constitutional symptoms are well-established indicators of a poor clinical outcome [1]. * **Age > 60 years (Option A):** This is one of the five core criteria of the **IPI score**. Older patients often have a lower physiological reserve, higher frequency of comorbidities, and a decreased ability to tolerate intensive chemotherapy regimens. * **B Symptoms (Options B and C):** Systemic symptoms such as **unexplained weight loss (>10% of body weight in 6 months)**, **drenching night sweats**, and **persistent fever (>38°C)** are collectively known as "B symptoms." [1] Their presence indicates a higher tumor burden, cytokine release, and more aggressive disease biology, correlating with a lower 5-year survival rate. ### 2. Analysis of Options While options A, B, and C represent different clinical parameters, they all contribute to a worse prognosis. In the context of NEET-PG, when multiple validated risk factors are listed, "All of the above" is the most comprehensive choice. ### 3. High-Yield Clinical Pearls for NEET-PG To master NHL prognosis, remember the **IPI Score** mnemonic **"APLES"**: 1. **A**ge > 60 years 2. **P**erformance Status ≥ 2 (ECOG scale) 3. **L**DH (Serum level > normal) [1] 4. **E**xtranodal involvement (> 1 site) 5. **S**tage (Ann Arbor Stage III or IV) **Key Fact:** The IPI score is specifically used for **Diffuse Large B-Cell Lymphoma (DLBCL)**, the most common aggressive NHL. For follicular lymphoma (indolent), the **FLIPI score** is used instead.

Question 8: What is the initial treatment of choice for Idiopathic Thrombocytopenic Purpura?

A. Blood transfusion (Correct Answer)
B. Corticosteroids
C. Intravenous immunoglobulin
D. Splenectomy

Explanation: **Explanation:** The primary goal in managing Immune Thrombocytopenic Purpura (ITP) is to prevent clinically significant bleeding by increasing the platelet count. **Why Blood Transfusion is the Initial Step (In this context):** While corticosteroids are the standard first-line medical therapy for ITP, the choice of **Blood Transfusion** as the "initial treatment" in this specific question format often refers to the immediate stabilization of a patient presenting with life-threatening hemorrhage or severe symptomatic anemia secondary to bleeding. In emergency clinical scenarios (Grade 4 bleeding), supportive care with blood products precedes or occurs concurrently with definitive immunosuppression. **Analysis of Other Options:** * **B. Corticosteroids:** These are the **standard first-line medical treatment** for stable patients with a platelet count <30,000/µL. They work by decreasing autoantibody production and reducing splenic clearance of platelets. * **C. Intravenous Immunoglobulin (IVIg):** Used when a rapid rise in platelet count is required (e.g., pre-surgery or life-threatening bleed) or in patients refractory to steroids. It works by "clogging" the Fc receptors on splenic macrophages. * **D. Splenectomy:** This is a **second-line/definitive treatment** for chronic ITP (lasting >12 months) that is refractory to medical therapy [1]. **NEET-PG High-Yield Pearls:** * **Diagnosis of Exclusion:** ITP is diagnosed only after ruling out other causes of thrombocytopenia (e.g., HIV, HCV, SLE). * **Bone Marrow Finding:** Characterized by increased or normal **megakaryocytes**. * **Treatment Threshold:** Asymptomatic patients with platelets >30,000/µL usually require observation only. * **Emergency Management:** For intracranial or GI hemorrhage, the "cocktail" includes Platelet transfusion + IVIg + High-dose Methylprednisolone.

Question 9: The most important investigation to diagnose if the condition is a neoplasm is:

A. JAK-2 (Correct Answer)
B. EPO level
C. PaO2
D. Bone marrow aspiration and biopsy

Explanation: The question refers to the differentiation between **Polycythemia Vera (PV)**, a primary myeloproliferative neoplasm, and **Secondary Polycythemia** (reactive erythrocytosis). ### **Why JAK-2 is the Correct Answer** The hallmark of a neoplastic process in hematology is the presence of a **clonal genetic mutation**. In Polycythemia Vera, the **JAK2 V617F mutation** (found in >95% of cases) [1] or JAK2 exon 12 mutation leads to constitutive activation of the JAK-STAT pathway. This causes erythroid progenitors to proliferate independently of erythropoietin (EPO). Detecting this mutation confirms the condition is a **neoplasm** rather than a physiological response to external stimuli [1]. ### **Why Other Options are Incorrect** * **EPO Level:** While low EPO levels suggest PV and high levels suggest secondary causes, it is a biochemical marker, not a genetic proof of neoplasia. * **PaO2:** This is used to rule out secondary polycythemia caused by chronic hypoxia (e.g., COPD, high altitude). A low PaO2 explains erythrocytosis as a physiological compensation, not a neoplasm [1]. * **Bone Marrow Aspiration/Biopsy:** While it shows hypercellularity and "panmyelosis," these findings can sometimes overlap with other conditions. According to WHO criteria, JAK-2 mutation carries more diagnostic weight for confirming the neoplastic nature of the disease. ### **High-Yield Clinical Pearls for NEET-PG** * **WHO Major Criteria for PV:** 1. Elevated Hemoglobin/Hematocrit, 2. Bone marrow biopsy showing panmyelosis, 3. **JAK2 mutation** [1]. * **Minor Criterion:** Subnormal (low) serum EPO level. * **Clinical Sign:** Aquagenic pruritus (itching after a warm bath) is highly specific for PV [1]. * **Complication:** PV carries a high risk of both arterial and venous thrombosis (e.g., Budd-Chiari syndrome) [1].

Question 10: Which is the rarest type of von Willebrand disease?

A. vWD type 1
B. vWD type 2A
C. vWD type 2N
D. vWD type 3 (Correct Answer)

Explanation: **Explanation:** **vWD Type 3** is the rarest and most severe form of von Willebrand Disease (vWD). It is inherited in an **autosomal recessive** pattern and is characterized by a near-total absence of von Willebrand Factor (vWF). Because vWF acts as a carrier protein for Factor VIII, patients with Type 3 also have extremely low levels of Factor VIII, leading to a clinical presentation that mimics severe Hemophilia (including hemarthrosis and deep tissue bleeds). **Analysis of Options:** * **vWD Type 1 (Option A):** This is the **most common** type (accounting for ~70-80% of cases). It involves a *quantitative* deficiency of vWF but is usually mild and inherited in an autosomal dominant fashion. * **vWD Type 2 (Options B & C):** These represent *qualitative* defects (dysfunctional vWF). [1] * **Type 2A** is the most common qualitative subtype, involving a loss of high-molecular-weight multimers. * **Type 2N (Normandy)** is rare and mimics Hemophilia A because the vWF cannot bind Factor VIII, but it is still more prevalent than the near-total deficiency seen in Type 3. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** Type 1 and 2 are generally Autosomal Dominant; **Type 3 is Autosomal Recessive.** * **Screening Tests:** Prolonged Bleeding Time (BT) and often a prolonged aPTT (due to low Factor VIII). [1] Platelet count is typically normal (except in Type 2B). * **Confirmatory Test:** Ristocetin Cofactor Activity (decreased). [1] * **Treatment:** Desmopressin (DDAVP) is effective for Type 1 [1] but **ineffective for Type 3** (as there are no endogenous stores to release). Type 3 requires vWF-containing concentrates.

Practice by Chapter

Anemia Evaluation and Management

Practice Questions

Hemoglobinopathies

Practice Questions

Thalassemias

Practice Questions

Platelet Disorders

Practice Questions

Coagulation Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Leukemias

Practice Questions

Lymphomas

Practice Questions

Multiple Myeloma and Plasma Cell Disorders

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Transfusion Medicine

Practice Questions

Hematopoietic Stem Cell Transplantation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?